Physician profile
Harwinder Singh
NPI 1346211620
$5,671.88
in general payments reported to CMS, 2019-2025
39 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,073 · 2020: $409 · 2021: $596 · 2022: $1,106 · 2023: $803 · 2024: $372 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,487.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,052.69 | 2019-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $560.40 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $429.13 | 2019-2025 | Relistor |
| Abbvie INC. | $423.86 | 2021-2023 | Ubrelvy, Qulipta, Botox |
| Collegium Pharmaceutical, INC. | $335.15 | 2019-2023 | Xtampza |
| Averitas Pharma INC. | $321.33 | 2023-2025 | Qutenza |
| Biodelivery Sciences International, INC. | $267.97 | 2019 | |
| Medtronic, INC. | $219.57 | 2022 | |
| Vision Quest Industries INC. | $161.77 | 2022 | |
| Forte Bio-Pharma LLC | $160.77 | 2021 | |
| Medtronic USA, INC. | $157.21 | 2019 | |
| Nevro Corp. | $134.68 | 2022 | |
| Biotronik Nro, INC. | $124.99 | 2024 | Prospera |
| Amgen INC. | $124.99 | 2019 | |
| Merck Sharp & Dohme LLC | $123.23 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harwinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.